MedPath

The research for the efficacy of adipose derived stem cell therapy for liver cirrhosis

Phase 2
Suspended
Conditions
iver cirrhosis
Registration Number
JPRN-jRCTb070200009
Lead Sponsor
Itano Satoshi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Suspended
Sex
All
Target Recruitment
6
Inclusion Criteria

Inclusion criteria
1.Clinically diagnosed as cirrhosis by CT and blood tests.
2.Child-Pugh score must be 6 points or more.
3.Must be between 20 and 90 years old.
4.Prior written consent to participate in the study must be obtained in writing.

Exclusion Criteria

Exclusion criteria
A. Patients whose abstinence cannot be expected during the treatment period
B. Patients with severe heart disease (obvious heart failure and arrhythmia)
C. Patients with hypersensitivity to the anesthetic used when collecting adipose tissue
D. Patients with uncontrolled malignant or intraepithelial neoplasia
E. Patients with uncontrollable infections
F. Pregnant women, lactating and possibly pregnant
G. Patients taking birth control pills
H. Patients who cannot give their informed consent
I. Patients who cannot evaluate the efficacy
J. Patients who can undergo other effective treatments, liver transplantation (living body and brain death)
K. Other patients who are judged to be inappropriate by the investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of liver function
Secondary Outcome Measures
NameTimeMethod
Improvement of liver fibrosis
© Copyright 2025. All Rights Reserved by MedPath